TRENDING :  Market Movers  |  Top 50   FDX (-2.8%)    SPY (-1.93%)    AMZN (-3%)    VXXB (11.47%)    LVS (-2.67%)    MCD (0.24%)    NFLX (-4.47%)    NRG (-2.03%)    NXST (-3.18%)    PBR (-7.22%)    PEI (0.33%)    POST (-0.17%)    PYPL (-2.77%)    QQQ (-2.2%)    ROKU (-4.53%)    SBUX (-0.42%)    SCIF (-3.28%)    SLNO (2.35%)    WYNN (-3.5%)    XLE (-2.71%)    XLF (-2.77%)    XLU (0.73%)    XRX (-5.6%)    ZUO (-14.06%)    SQ (-4.39%)

 AUPH - Aurinia Pharmaceuticals Inc

$6.47 [-0.29][-4.15%]

Next Earnings



Trade Idea »


Quarterly Rating Chart


1=Strong Buy, 2=Buy, 3=Hold, 4=Underperform, 5=Sell
Price Targets
High $11.00
Low $11.00
Average $11.00
Current $6.47

CompanyAnalyst NamePT ActionActionRatingTargetDate
Raymond JamesRaisesMaintainsStrong Buy$11.0003/20/19
*Last 90 days


No recommendations found.

This list is limited to recommendations made in last 7 days only. Subscribe to a service to see all their recommendations.



Aurinia Pharmaceuticals Inc (AUPH) Q4 2018 Earnings Conference Call Transcript

Image source The Motley Fool Aurinia Pharmaceuticals Inc NASDAQ AUPH Q4 2018 Earnings Conference Call March 19 2019 4 30 p m ET Contents Prepared Remarks Questions and Answers Call Participants Prepared Remarks

After-Hours Earnings Report for March 19, 2019 : FDX, FNV, SCS, AIR, AUPH, ATTO, METC, WPRT, IDXG

The following companies are expected to repor t earnings after hours on 03 19 2019 Visit our Earnings Calendar for a full list of expected earnings releases FedEx Corporation FDX is reporting for the quarter ending February 28 2019 The

Analysts Estimate Aurinia Pharmaceuticals (AUPH) to Report a Decline in Earnings: What to Look Out for

Aurinia Pharmaceuticals AUPH is expected to deliver a year over year decline in earnings on higher revenues when i t report s results for the quarter ended December 2018 This widely known consensus outlook gives a good sense of the company s earnings picture but how the actual results

After Patent News, Aurinia Pharmaceuticals Still Has More to Prove

InvestorPlace Stock Market News Stock Advice amp Trading Tips Aurinia Pharmaceuticals NASDAQ AUPH leapt close to 20 on Monday AUPH stock took off after the announcement of a new patent for the application method of its lupus nephritis drug Source Shutterstock

5 Clinical Stage Biotech Stocks to Buy

InvestorPlace Stock Market News Stock Advice amp Trading Tips Last year was not kind to many biotech stocks When investors abandoned high growth equities as the economy and market got rocky biotech stocks were some of the first to go This was especially true for many of

Here's Why Aurinia Pharmaceuticals' Stock Jumped Today

What happened Shares of Aurinia Pharmaceuticals NASDAQ AUPH 160 a clinical stage biopharmaceutical company are on the move after the U S Patent and Trademark Office USPTO issued an important notice Investors looking forward to long term market exclusivity pushed the